0      0


JL1110EH - JL1110EH: Indirect treatment comparison of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.


Full author listing

Lucia Masarova,1 Srdan Verstovsek,1 Francesca Palandri,2 Ruben Mesa,3 Claire Harrison,4 Balázs Dobi,5 Boris Gorsh,6 Zhaohui Wang,6 Catherine Ellis,6 Dwaipayan Patnaik,6 Venediktos Kapetanakis7

Affiliations:

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3Wake Forest University School of Medicine, Winston-Salem, NC, USA; 4Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 5Evidera, Budapest, Hungary;6GSK plc, Philadelphia, PA, USA; 7Evidera, London, UK


Presenter(s):

You must be logged in and own this session in order to post comments.